BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int. 2010;4:577-584. [PMID: 21063480 DOI: 10.1007/s12072-010-9197-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
2 Wei F, Zheng Q, Li M, Wu M. The association between hepatitis B mutants and hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2017;96:e6835. [PMID: 28489767 DOI: 10.1097/MD.0000000000006835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
3 Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A, Zakaria MK, Fatima K, Ahmad S, Azhar E, Chaudhary A, Qadri I. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10238-10248 [PMID: 25132741 DOI: 10.3748/wjg.v20.i30.10238] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
4 Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn. 2014;14:803-817. [PMID: 25098554 DOI: 10.1586/14737159.2014.946908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Chuaypen N, Payungporn S, Poovorawan K, Chotiyaputta W, Piratvisuth T, Tangkijvanich P. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes 2019;55:610-8. [PMID: 31359359 DOI: 10.1007/s11262-019-01689-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Yeh CS, Hsu CW, Liang KH, Chen YC, Lin CL, Chien RN, Hu TH, Lin WR, Lai MW, Chu YD, Yeh CT. Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. J Gastroenterol Hepatol 2018;33:1530-7. [PMID: 29424069 DOI: 10.1111/jgh.14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Xie Y, Liu S, Zhao Y, Guo Z, Xu J. X protein mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma. Tumour Biol. 2014;35:10325-10331. [PMID: 25034530 DOI: 10.1007/s13277-014-2331-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
8 Wang Y, Zeng LI, Chen W. HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2016;4:1045-51. [PMID: 27284442 DOI: 10.3892/mco.2016.847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
9 Song XM, Li QL, Guo F, Peng H, Guo JJ. The Effect of ICOS Polymorphism Interactions with HBV Mutations on HBV Subtype Infection Outcomes. Ann Hepatol 2018;17:940-7. [PMID: 30600290 DOI: 10.5604/01.3001.0012.7194] [Reference Citation Analysis]
10 Martinez AA, Zaldivar Y, Hong CCh, Alvarado-Mora MV, Smith R, Ortiz AY, Pinho JR, Cristina J, Pascale JM. Molecular characterisation of hepatitis B virus in the resident Chinese population in Panama City. Mem Inst Oswaldo Cruz. 2013;108:541-547. [PMID: 23903967 DOI: 10.1590/s0074-02762013000500002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Park YM, Jang JW, Yoo SH, Kim SH, Oh IM, Park SJ, Jang YS, Lee SJ. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat. 2014;21:171-177. [PMID: 24344773 DOI: 10.1111/jvh.12134] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
13 Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget. 2016;7:12525-12536. [PMID: 26848866 DOI: 10.18632/oncotarget.7123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
14 Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, Lin YJ, Yen CJ, Cheng PN, Li PF, Cheng YT, Cheng PW, Sun KT, Yan SL, Lin JJ, Yang JC, Chang KC, Ho CH, Tseng VS, Chang BC, Wu JC, Chang TT. Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J Pathol 2017;243:176-92. [PMID: 28696069 DOI: 10.1002/path.4938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
15 Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016;36:827-36. [DOI: 10.1111/liv.13046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
16 Park YM. Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome. World J Hepatol 2015; 7(1): 113-120 [PMID: 25625002 DOI: 10.4254/wjh.v7.i1.113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, Yan R, Hu CT, Guo H, Block TM, Song W, Su YH. Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep 2015;5:10478. [PMID: 26000761 DOI: 10.1038/srep10478] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
18 Chuaypen N, Sriprapun M, Praianantathavorn K, Payungporn S, Wisedopas N, Poovorawan Y, Tangkijvanich P. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130-138. [PMID: 27307409 DOI: 10.1002/jmv.24601] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
19 Xu Z, Wu G, Li F, Bai J, Xing W, Zhang D, Zeng C. Positive selection signals of hepatitis B virus and their association with disease stages and viral genotypes. Infection, Genetics and Evolution 2013;19:176-87. [DOI: 10.1016/j.meegid.2013.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]